目的 观察葛根素葡萄糖注射液联合苯磺酸氨氯地平治疗冠心病心绞痛的临床疗效。方法 选取鞍钢集团总医院2014年5月-2016年5月收治的冠心病心绞痛患者80例，依据治疗方法不同分为对照组和治疗组，每组各40例。对照组患者口服苯磺酸氨氯地平片，5 mg/次，1次/d。治疗组患者在对照组的基础上静脉滴注葛根素葡萄糖注射液，500 mg加入5%葡萄糖注射液250 mL，1次/d。两组患者均连续治疗1个月。观察两组的临床疗效，同时比较分析两组患者心绞痛发作频率、持续时间及硝酸甘油用量、左室收缩功能和不良反应发生情况。结果 治疗后，对照组和治疗组总有效率分别为70.0%和92.5%，两组比较差异具有统计学意义（P<0.05）。治疗后两组心绞痛发作次数、持续时间及硝酸甘油用量较同组治疗前明显降低，同组比较差异具有统计学意义（P<0.05）；且治疗后，治疗组心绞痛改善情况优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者每搏射血量（SV）、心脏指数（CI）和射血分数（LVEF）变化比较差异均没有统计学意义。治疗后，两组不良反应发生率比较差异没有统计学意义。结论 葛根素注射液联合苯磺酸氨氯地平治疗冠心病心绞痛具有显著的疗效，具有一定的临床推广应用价值。

Objective To observe the clinical efficacies of Puerarin and Glucose Injection combined with amlodipine besylate in treatment of coronary heart disease with angina pectoris. Methods Patients (80 cases) with coronary heart disease with angina pectoris from May 2014 to May 2016 in Ansteel Group Hospital were divided into control and treatment groups based on different treatments, and each group had 40 cases. Patients in the control group were po administered with Amlodipine Besylate Tablets, 5 mg/time, once daily. The patients in the treatment group were iv administered with Puerarin and Glucose Injection on the basis of the control group, 500 mg added into 5% glucose injection, once daily. The patients in two groups were treated for one month. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, nitroglycerin dosage, left ventricular systolic function, and adverse reactions in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 70.0% and 92.5%, respectively, and there were differences between two groups (P<0.05). After treatment, frequency and duration of angina pectoris, and also nitroglycerin dosage of two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And after treatment, the improvement of symptoms in the treatment group was better than that in the control group, with significant differences between two groups (P<0.05). After treatment, there was no statistically significant difference in the changes of SV, CI, and LVEF between two groups. And after treatment, the differences were not statistically significant in the adverse reactions between two groups. Conclusion Puerarin and Glucose Injection combined with amlodipine besylate has a significant clinical efficacy in treatment of coronary heart disease with angina pectoris, which has a certain clinical application value.